Turning Point Therapeutics, Inc. announced the appointment of Adam Levy, Ph.D., MBA, as senior vice president of Investor Relations and Corporate Communications, effective November 8, 2021. Dr. Levy brings more than 20 years of experience to the company, including a strong background in investor relations, corporate strategy and communications. Prior to joining the company, he served as executive vice president of Corporate Development and Investor Relations at Ziopharm Oncology. Previously, Dr. Levy served as executive director of Investor Relations and head of Corporate Strategy for Gilead Sciences. He has also held senior level and executive positions at Alexion, Bristol Myers Squibb, Novartis, and Pfizer Animal Health (now Zoetis). Dr. Levy was also previously a consultant at McKinsey & Company, serving clients in their Healthcare practice. In addition, the company announced that Scott Lipman, MBA, has been appointed to the newly created position of chief of staff. Lipman joined the company in early 2020 and has played an integral role on the business development and strategy, and investor relations teams at the company. He most recently served as senior director of Corporate and Business Development. Prior to joining the company, Lipman worked in Healthcare Investment Banking at Goldman Sachs, where he advised management teams on a range of strategic financial matters, executed financings as well as M&A transactions. He also has worked as a management consultant at ZS Associates, advising biopharma clients on a range of strategic issues, including commercial planning, lifecycle planning, and business development and licensing.